Overview
Chronic thromboembolic pulmonary hypertension, or CTEPH, is a serious form of pulmonary hypertension caused by chronic blood clots that obstruct the pulmonary arteries and raise pressure in the lungs. One important treatment option is balloon pulmonary angioplasty, commonly called BPA, a catheter-based procedure that opens narrowed or blocked pulmonary arteries using small inflatable balloons.
In many patients, doctors use pulmonary hypertension-targeted medical therapy before BPA to reduce strain on the right side of the heart and improve hemodynamics. This study from the Dutch BPA registry examined whether pretreatment with dual targeted therapy offers better safety and clinical benefit than monotherapy.
